Rocket Pharmaceuticals Stock Rises 4% on $150M Credit Facility

Key Facts

1Rocket Pharmaceuticals secured access to up to $150 million under a credit facility with Hercules Capital.

2Shares rose 4% following the announcement aimed at supporting the Phase 2 study of RP-A501 and the cardiovascular pipeline.

Rocket Pharmaceuticals secured access to a credit facility of up to $150 million from Hercules Capital. Proactive Investors reported that the company's shares rose 4% following the announcement, which is intended to strengthen Rocket's financial position and fund the pivotal Phase 2 study of RP-A501 for Danon disease.

RCKT closed at $2.48 on October 6, 2026, while HTGC, the ticker for Hercules Capital, closed at $16.57 on the same date. According to the company, the facility provides additional capital to support its broader cardiovascular pipeline as it works toward completing pivotal trial dosing by mid-2027.